title: Effects of growth hormone secretagogues in the transgenic growth-retarded (Tgr) rat.
abstract: Exogenous GH inhibits endogenous GH release by hypothalamic feedback. We have recently exploited this to generate transgenic growth-retarded (Tgr) rats, in which human GH is expressed in the hypothalamus, under the control of the rat GRF gene promoter. These rats show reduced pituitary size, GH deficiency, and dominant dwarfism, but are large enough for serial blood sampling studies to examine their spontaneous GH secretion and responses to GRF, somatostatin, and GH-releasing peptide-6 (GHRP-6). Like their normal wild-type littermates, Tgr rats show a sexually dimorphic pattern of GH secretion; males secrete GH in 3-h episodes, whereas females exhibit a more continuous irregular output, with higher baseline GH levels. In anesthetized male Tgr rats, the GH responses to GRF or GHRP-6 were markedly reduced compared with those of their nontransgenic littermates, but the differences were smaller in females. Despite the reduction in pituitary GH, peak plasma GH responses to serial GRF injections in conscious Tgr males or intermittent somatostatin infusions in conscious Tgr females were indistinguishable from the responses in their wild-type littermates. Furthermore, 7-day iv infusions of GRF (12.5-100 micrograms/day), given either continuously or as a pulsatile infusion stimulated growth in Tgr rats, as did pulsatile infusions of GHRP-6. Thus, despite their pituitary GH deficiency and dwarfism, Tgr rats maintain a sexually dimorphic pattern of GH release and can produce large GH secretory responses to exogenous secretagogues. They represent the first genetic model of GH deficiency in the rat in which dwarfism can be corrected by treatment with exogenous GH secretagogues.
authors.affiliation: Division of Neurophysiology, National Institute for Medical Research, London, United Kingdom.
authors.forename: T
authors.initials: T
authors.lastname: Wells
authors.forename: D M
authors.initials: DM
authors.lastname: Flavell
authors.forename: S E
authors.initials: SE
authors.lastname: Wells
authors.forename: D F
authors.initials: DF
authors.lastname: Carmignac
authors.forename: I C
authors.initials: IC
authors.lastname: Robinson
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D004392:Dwarfism / Q000235:genetics*; D005260:Female; D013006:Growth Hormone / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D012727:Sex Characteristics; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D009842:Oligopeptides; C041048:growth hormone releasing hexapeptide; D013004:Somatostatin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone